Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 9, 2009, Pages 973-983

  Kathirvel, Elango ^a,b   Morgan, Kengathevy ^a,b   French, Samuel W ^c   Morgan, Timothy R ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Cytochrome P4502E1; Insulin resistance; Nonalcoholic fatty liver disease; Oxidative stress

Indexed keywords

ACTIVATED PROTEIN C; ALANINE AMINOTRANSFERASE; ALBUMIN; CARBONYL DERIVATIVE; CYTOCHROME P450 2E1; GLUCOSE; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3ALPHA; INSULIN; INSULIN RECEPTOR; MALONALDEHYDE; PHOSPHOENOLCARBOXYKINASE; PHOSPHOTRANSFERASE; SERINE; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CALORIE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE MODEL; ENHANCER REGION; GLUCONEOGENESIS; GLYCOGEN ANALYSIS; HISTOLOGY; INSULIN RESISTANCE; LIPID STORAGE; LIVER CELL; LIVER INJURY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CARBONYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; WESTERN BLOTTING;

ALANINE TRANSAMINASE; ANIMALS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CELL LINE; CYTOCHROME P-450 CYP2E1; FATTY LIVER; HEPATOCYTES; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, TRANSGENIC; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 69549138691     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328328f461     Document Type: Article

References (52)

1. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122:1649-1657.
2. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21:17-26. (Pubitemid 32240483)
3. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008; 115:141-150.
4. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107:450-455. (Pubitemid 29528333)
5. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999; 18:353-358.
6. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50:1844-1850. (Pubitemid 33641605)
7. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120:1183-1192. (Pubitemid 32246672)
8. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15:539-553.
9. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106:171-176.
10. Gual P, Gonzalez T, Gremeaux T, Barres R, Le Marchand-Brustel Y, Tanti JF. Hyperosmotic stress inhibits insulin receptor substrate-1 function by distinct mechanisms in 3T3-L1 adipocytes. J Biol Chem 2003; 278:26550-26557. (Pubitemid 36876798)
11. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-789. (Pubitemid 26004411)
12. Nakae J, Biggs WH 3rd, Kitamura T, Cavenee WK, Wright CV, Arden KC, et al. Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet 2002; 32:245-253.
13. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003; 423:550-555. (Pubitemid 36648580)
14. Zhang X, Gan L, Pan H, Guo S, He X, Olson ST, et al. Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding. J Biol Chem 2002; 277:45276-45284. (Pubitemid 36159133)
15. Meigs JB, Larson MG, Fox CS, Keaney JF Jr, Vasan RS, Benjamin EJ. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. Diab Care 2007; 30:2529-2535.
16. McCubrey JA, Lahair MM, Franklin RA. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal 2006; 8:1775-1789. (Pubitemid 44726351)
17. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420:333-336. (Pubitemid 35398190)
18. Albano E, Mottaran E, Occhino G, Reale E, Vidali M. Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther 2005; 22 (Suppl 2):71-73. (Pubitemid 41564388)
19. Yang S, Zhu H, Li Y, Lin H, Gabrielson K, Trush MA, et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000; 378:259-268. (Pubitemid 30397626)
20. Zou Y, Li J, Lu C,Wang J, Ge J, Huang Y, et al. High-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Life Sci 2006; 79:1100-1107. (Pubitemid 44102717)
21. Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24:200-208. (Pubitemid 26059117)
22. Lieber CS. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998) - a review. Alcohol Clin Exp Res 1999; 23:991-1007.
23. Lieber CS. Cytochrome P-4502E1: its physiological and pathological role. Physiol Rev 1997; 77:517-544. (Pubitemid 27184347)
24. Ingelman-Sundberg M, Ronis MJ, Lindros KO, Eliasson E, Zhukov A. Ethanol inducible cytochrome P4502E1: regulation, enzymology and molecular biology. Alcohol Alcoholism 1994; 2:131-139.
25. Koop DR. Alcohol metabolism's damaging effects on the cell: a focus on reactive oxygen generation by the enzyme cytochrome P450 2E1. Alcohol Res Health 2006; 29:274-280.
26. White RE, Coon MJ. Oxygen activation by cytochrome P-450. Annu Rev Biochem 1980; 49:315-356.
27. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27:128-133. (Pubitemid 28041545)
28. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111:1645-1653. (Pubitemid 26404230)
29. Schattenberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. J Biol Chem 2005; 280:9887-9894. (Pubitemid 40395836)
30. Morgan K, Uyuni A, Nandgiri G, Mao L, Casteneda L, Kathirvel E, et al. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2008; 20:843-854.
31. Morgan K, French SW, Morgan TR. Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology 2002; 36:122-134. (Pubitemid 34700769)
32. Reznick AZ, Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 1994; 233:357-363. (Pubitemid 24177561)
33. Liu J, Yeo HC, Doniger SJ, Ames BN. Assay of aldehydes from lipid peroxidation: gas chromatography-mass spectrometry compared to thiobarbituric acid. Anal Biochem 1997; 245:161-166. (Pubitemid 27082245)
34. Van Der Vies J. Two methods for the determination of glycogen in liver. Biochem J 1954; 57:410-416.
35. Liu H, Jones BE, Bradham C, Czaja MJ. Increased cytochrome P-450 2E1 expression sensitizes hepatocytes to c-Jun-mediated cell death from TNF-alpha. Am J Physiol Gastrointest Liver Physiol 2002; 282:G257-G266. (Pubitemid 34651682)
36. Lee YH, Giraud J, Davis RJ, White MF. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 2003; 278:2896-2902. (Pubitemid 36801194)
37. Videla LA, Rodrigo R, Orellana M, Fernandez V, Tapia G, Quinones L, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond) 2004; 106:261-268. (Pubitemid 38365832)
38. Caro AA, Cederbaum AI. Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol 2004; 44:27-42.
39. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 2005; 7:1040-1052. (Pubitemid 40967154)
40. Eriksson JW. Metabolic stress in insulin's target cells leads to ROS accumulation-a hypothetical common pathway causing insulin resistance. FEBS Lett 2007; 581:3734-3742.
41. Pi J, Bai Y, Zhang Q,Wong V, Floering LM, Daniel K, et al. Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes 2007; 56:1783-1791. (Pubitemid 47025446)
42. Eliasson E, Johansson I, Ingelman-Sundberg M. Ligand-dependent maintenance of ethanol-inducible cytochrome P-450 in primary rat hepatocyte cell cultures. Biochem Biophys Res Commun 1988; 150:436-443. (Pubitemid 18036252)
43. Roberts BJ, Song BJ, Soh Y, Park SS, Shoaf SE. Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1. J Biol Chem 1995; 270:29632-29635. (Pubitemid 26001620)
44. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006; 440:944-948.
45. Haque M, Sanyal AJ. The metabolic abnormalities associated with non-alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2002; 16:709-731. (Pubitemid 38001859)
46. Adler V, Yin Z, Tew KD, Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. Oncogene 1999; 18:6104-6111.
47. Torres M. Mitogen-activated protein kinase pathways in redox signaling. Front Biosci 2003; 8:d369-d391.
48. Orellana M, Rodrigo R, Varela N, Araya J, Poniachik J, Csendes A, et al. Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. Hepatol Res 2006; 34:57-63. (Pubitemid 43091877)
49. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279:32345-32353. (Pubitemid 39014687)
50. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293:1673-1677. (Pubitemid 32807849)
51. Matsuzawa-Nagata N, Takamura T, Ando H, Nakamura S, Kurita S, Misu H, et al. Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. Metabolism 2008; 57:1071-1077. (Pubitemid 351978066)
52. Fridlyand LE, Philipson LH. Reactive species and early manifestation of insulin resistance in type 2 diabetes. Diabetes Obes Metab 2006; 8:136-145.